Pitt Shield

Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound.

Authors: Yang FY, Teng MC, Lu M, Liang HF, Lee YR, Yen CC, Liang ML, Wong TT

High-dose tissue-specific delivery of therapeutic agents would be a valuable clinical strategy. We have previously shown that repeated transcranial focused ultrasound is able to increase the delivery of Evans blue significantly into brain tissue. The present study shows that repeated pulsed high-intensity focused ultrasound (HIFU) can be used to deliver high-dose atherosclerotic plaque-specific peptide-1 (AP-1)-conjugated liposomes selectively to brain tumors. Firefly luciferase (Fluc)-labeled human GBM8401 glioma cells were implanted into NOD-scid mice. AP-1-conjugated liposomal doxorubicin or liposomal doxorubicin alone was administered followed by pulsed HIFU and the doxorubicin concentration in the treated brains quantified by fluorometer. Growth of the labeled glioma cells was monitored through noninvasive bioluminescence imaging and finally the brain tissue was histologically examined after sacrifice. Compared with the control group, the animals treated with 5 mg/kg injections of AP-1 liposomal doxorubicin or untargeted liposomal doxorubicin followed by repeated pulsed HIFU not only showed significantly enhanced accumulation of drug at the sonicated tumor site but also a significantly elevated tumor-to-normal brain drug ratio (P < 0.001). Combining repeated pulsed HIFU with AP-1 liposomal doxorubicin or untargeted liposomal doxorubicin has similar antitumor effects. This study demonstrates that targeted or untargeted liposomal doxorubicin, followed by repeated pulsed HIFU, is a promising high-dose chemotherapy method that allows the desired brain tumor region to be targeted specifically.

Introduction

Purpose Drug delivery with BBB opening
Study Objective To determine whether repeated pulsed high-intensity focused ultrasound (HIFU) can enhance selective delivery and tumor accumulation of AP-1–targeted liposomal doxorubicin to intracranial gliomas.
Animal model / Human subject Mouse (Mus musculus), NOD‑scid strain, age None, sex None
Disease model Glioma (glioblastoma brain tumor)
MRI or image guidance method Noninvasive bioluminescence imaging was used to monitor and localize the Fluc-labeled glioma for FUS targeting; no MRI or stereotactic guidance is reported.
Targeted brain region(s) Brain Tumor (Glioma; Gbm8401 Xenograft)
Cargo name and characteristics AP-1-conjugated liposomal doxorubicin (and untargeted liposomal doxorubicin): liposomal nanoparticle formulation encapsulating the small-molecule anthracycline chemotherapeutic doxorubicin; used at 5 mg/kg, with one variant surface-conjugated to atherosclerotic plaque-specific peptide-1 (AP-1) for tumor targeting.
Route of administration intravenous injection

Outcomes and Safety

Summary of Outcomes Repeated pulsed high-intensity focused ultrasound markedly increased accumulation and tumor-to-normal brain ratio of liposomal doxorubicin (targeted or untargeted), enhancing antitumor effects against intracranial glioma without increasing systemic toxicity.
Duration of biological effect 7 days
Safety-related matter Authors note concerns about systemic toxicity of doxorubicin and potential tissue damage from sonication, but report no significant body-weight changes and conclude repeated pulsed HIFU enables local high-dose delivery without increasing systemic toxicity.

Brain Region

Ultrasound Parameters

Ultrasound instrument None.
FUS Frequency None in text
FUS Mode pulsed
Duration of a single FUS session None.
Treatment frequency multiple sessions

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search